Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology …,

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687., Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687., Read More

Scroll to Top